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A number of preclinical and clinical studies have reported blood-pressure-lowering benefits of thiazolidinediones in diabetic
subjects and animal models of diabetes. This study was designed to further elucidate vascular effects of rosiglitazone, on healthy
nonobese, lean animals. Adult male Wistar rats were randomized and assigned to control and rosiglitazone-treated groups and
were dosed daily with either vehicle or rosiglitazone (10 mg kg−1 day−1) by oral gavage for 5 days. Compared with control group,
rosiglitazone treatment significantly reduced plasma levels of triglycerides (>240%) and nonesterified free fatty acids (>268%)
(both, P < 0.001). There were no changes in vascular contractility to KCl or noradrenaline between two groups. However,
rosiglitazone therapy improved carbamylcholine-induced vasorelaxation (93 ± 3% versus control 78 ± 2, P < 0.01) an effect
which was abolished by L-NAME. There was no difference in sodium nitroprusside-induced vasorelaxation between the control
and rosiglitazone-treated animals. These results indicate that short-term rosiglitazone therapy improves bothmetabolic profile and
vascular function in lean rats. The vascular effect of rosiglitazone appears to be mediated by alteration in NO production possibly
by activation of endothelial PPARγ. This increased NO production together with improved lipid profile may explain mechanism(s)
of blood-pressure-lowering effects of thiazolidinediones on both human and experimental animals.
1. Introduction
Metabolic syndrome (syndrome X), known as a cluster of
insulin resistance, abnormal glucose tolerance, abdominal
obesity, dyslipidaemia, and arterial disease [1], is associated
with substantially increased risk of cardiovascular disease
resulting in increased morbidity and premature mortality.
Insulin resistance is thought to be the primary abnormality
in syndrome X. The increased cardiovascular disorders seen
in syndrome X are thought to be consequences of at least
(a) alterations in direct effects of insulin on vascular smooth
muscle proliferation [2], (b) indirect effects via activation
of the sympathetic nervous system [3], and (c) resistance to
vasodilator effects of insulin [4].
The role of endothelium in the regulation of vascular
tone by producing various vasoactive mediators which
include nitric oxide (NO) and endothelin, both of which
acting on the underlying vascular smooth muscle to mod-
ulate arterial contractility, is well understood. Impaired
endothelium-dependent vasorelaxation has been demon-
strated in obesity, type 2 diabetes, and hypertension [5–
7] with the most striking abnormality being attenuation of
acetylcholine-induced NO-dependent vasodilatation.
Thiazolidinediones (TZDs), such as pioglitazone and
rosiglitazone, are effective in the management of type
2 diabetes mellitus. They bind to the nuclear peroxi-
some proliferator-activated receptor-γ (PPAR-γ), and con-
sequential improvements in insulin resistance and glucose
metabolism are principally attributed to decreased free
fatty acid concentrations [8, 9]. They improve metabolic
abnormalities in animal models of insulin resistance and
type 2 diabetes [5, 10] and in human subjects with type
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2 diabetes mellitus [11, 12]. A variety of studies have
suggested that thiazolidinediones may also have independent
beneficial effects on the vasculature. These included lowering
of blood pressure in fatty Zucker rats [13], genetically obese
diabetic rats [14], diet-induced hypertensive rats [15], and,
Dahl salt-sensitive rats [16]. Moreover, TZDs have been
reported to reduce vascular adverse remodeling, and preserve
intramyocardial vascularization in renovascular hypertensive
rats (2K1C model) [17] as well as direct vasorelaxant effect
and endothelial protective effects on arteries from obese
Zucker rats [18, 19]. Similar studies in human subjects with
type 2 diabetes mellitus have reported endothelial function
improvement [20, 21]. Therefore, it appears that TZDs have
a significantly positive effects on vascular function.
On examination of the effects of the TZD on metabolic
and/or cardiovascular function, a vast majority of the animal
or human studies are performed on well-established disease
status. Thus, it is not possible to extrapolate if an early
intervention by TZD’s would also have a significant effect
on cardiovascular function in prediabetic status. Hence, this
study was designed to evaluate vascular effects of acute (5
day) administration of rosiglitazone in chowfed male Wistar
rats. In this study, resistance arteries were deployed to mea-
sure vascular function, as these vessels represent endothelial
function throughout the vasculature and are believed to be
involved in determining the increase in peripheral resistance
that leads to the development of hypertension [22].
2. Material and Methods
2.1. Animals. Adult (12-week-old) male Wistar rats (n = 20)
were randomized and assigned to a control group (n =
10, 300.2 ± 5.4 g) and a rosiglitazone-treated group (n =
10, 302.5 ± 4.9 g). All animals had free access to standard
laboratory pelleted diet (CRM Biosure, Cambridge, UK)
and water. They were housed in pairs under controlled
environmental conditions (19–22◦C; 30–40% humidity) and
a 12-hour light/dark cycle (lights on at 08:00 h). All animals
were dosed at 08:00 daily for 5 days with either vehicle
(1% carboxymethyl cellulose at 3mL kg−1 body weight) or
rosiglitazone (10mg kg−1 day−1) by oral gavage.
The rats were killed 2 hours after last dose by CO2
inhalation. Blood was removed by cardiac puncture into
cold heparinized tubes and hematocrit levels were measured.
The gonadal and perirenal fat pads and the gastrocnemius
muscle were dissected and weighed. Plasma was immediately
separated by centrifugation before being frozen for later
measurements of nonesterified free fatty acids (NEFA) and
triglycerides (TG), using commercially available diagnostic
kits (Roche & Sigma Diagnostics, resp.).
2.2. Assessment of Vascular Function. Four third-order
mesenteric arteries (<250 μm diameter, 2mm lengths) were
carefully dissected from each animal. Each artery was freed
of fat and connective tissue and mounted on two 40 μm
diameter stainless-steel wires in an automated myograph
(Cambustion, Cambridge, UK), based on the principle of
the Mulvany myograph. The vessels (in duplicate) were
incubated in a 5mL organ bath containing physiological salt
solution (PSS; composition [in mM]: NaCl 119, KCl 4.7,
CaCl2 2.5, MgSO4 1.17, NaHCO3 25, KH2PO4 1.18, EDTA
0.026 and glucose 5.5) gassed with 95% O2 and 5% CO2 at
37◦C.
After 30min equilibration, the length-tension character-
istics for each vessel were determined as described previously
[23]. The computer also calculated the target tension that
each vessel should develop in response to a maximal
stimulus. Arteries were then allowed a further 30min to equi-
librate before being depolarized twice with high-potassium
physiological salt solution (KPSS, 125mM), in which NaCl
in normal PSS was replaced by an equimolar concentration
of KCl. Any vessel failing to reach its predetermined target
tension in response to vasoconstriction with KCl (125mM)
was discarded. Cumulative concentration-response curves to
either KCl (10–125mM) or noradrenaline (NA, 0.5–6 μM)
were then carried out.
2.3. Assessment of Endothelium-Dependent and -Independent
Vascular Relaxation. Changes in endothelial-dependent and
-independent vascular functions were assessed by observ-
ing any alterations invascular reactivity to carbamyl-
choline (CCh), and sodium nirtoprusside (SNP) in NA-
preconstricted arteries. Arteries were contracted with a
supramaximal concentration of NA (8 μM). When con-
traction reached a plateau after 2 minutes, concentration-
response curves were carried out to either CCh or SNP
(for both, 10 nM–100 μM). Vascular responses to CCh were
measured in absence or presence of L-NAME (100 μM).
2.4. Reagents. Noradrenaline, carbamylcholine, sodium
nitroprusside (SNP), N(G)-nitro-L-arginine methyl ester
(L-NAME), rosiglitazone, and carboxymethyl cellulose were
all obtained from Sigma Chemicals (UK). Noradrenaline,
CCh, SNP, and L-NAMEwere all dissolved in double distilled
water. Both noradrenaline and SNP were kept away from
light throughout the experiment. All water-soluble solutions
were freshly made on the day of the experiment.
2.5. Data Interpretation and Statistical Analyses. Vasocon-
striction in response to NA and KCl were expressed as abso-
lute force generated. Vasorelaxation responses to CCh and
SNP were calculated as the percentage reduction from the
maximal tension generated in response to the supramaximal
concentration of NA (8 μM). Data are expressed as mean
± S.E.M. Statistical significance was tested using repeated-
measures ANOVA or the Mann-Whitney test, as appropriate.
Results were considered statistically significant at the P < 0.05
levels.
3. Results
3.1. Body Weight and Metabolic Data. There were no signif-
icant differences in body weight (P = 0.399), and perirenal
fat pad mass (P = 0.239), and gastrocnemius muscle mass
(P = 0.659) between two experimental groups (Table 1).
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Table 1: Physiological and metabolic characteristics of the 2
experimental groups. Data are mean ± SEM.
Controls Rosiglitazone
(n = 10) (n = 10)
Body weight (g)
(i) Initial 300.2± 5.4 302.7± 4.9
(ii) Final 325.5± 5.6 339.9± 8.7
Gonadal fat-pad mass (g) 1.13± 0.06 1.47± 0.09a
Perirenal fat-pad mass (g) 1.12± 0.08 1.31± 0.12
Gastrocnemius muscle mass (g) 1.86± 0.05 1.92± 0.06
Fat/lean ratio∗ 1.23± 0.07 1.45± 0.08
Plasma triglycerides (mM) 1.34± 0.11 0.50± 0.04b
Plasma NEFA (mM) 0.20± 0.01 0.08± 0.00b
Total cholesterol 2.33± 0.10 2.40± 0.96
HDL cholesterol 0.92± 0.08 1.01± 0.08
LDL cholesterol 2.12± 0.20 2.66± 0.17
Hematocrit 45.9± 0.2 41.8± 0.5b
∗
Fat/Lean ratio = sum of white fat pad masses/gastrocnemius muscle mass;
aP < 0.01, bP < 0.001 versus controls.
However, compared with control groups, rosiglitazone-
treated animals, had significantly higher gonadal fat pad
mass (P < 0.01), and lower hematocrit (P < 0.001) (Table 1).
The increase in gonadal fat pad mass in turn translated to
an increase in fat/lean ratio in rosiglitazone-treated animals,
compared with their counterpart control group. However,
this increase in fat/lean ratio was not statistically significant
from that of control group (P = 0.0830) (Table 1).
Rosiglitazone significantly lowered plasma levels of
triglycerides (>240%) and NEFA (>268%) (for both, P <
0.001) than control animals; however, it had no effects on
plasma levels of total cholesterol, LDL, and HDL.
3.2. Vascular Responses. There were no significant differences
in arterial diameter between two groups in this study.
3.3. Contractile Responses. There were no significant dif-
ferences in KCl-induced arterial contraction between the
two groups. KCl concentration-response curves in both
groups produced similar maximal contractile generated
forces (control: 7.29 ± 0.50 versus rosiglitazone-treated: 7.23
± 0.38mN). Similar outcome was also seen with NA-
induced contractility. NA-induced contractile curves were
similar between control and rosiglitazone-treated animals,
producing comparable maximal contractions between two
groups (control: 13.99 ± 1.21 versus rosiglitazone-treated:
13.33 ± 0.89) (Figure 1).
3.4. Endothelium-Dependent Relaxation. Arteries from
rosiglitazone-treated rats showed significant (P < 0.001)
increase in vasorelaxation response to CCh compared
with that of control animals (rosiglitazone-treated: 93
± 3%versus control 78 ± 2 (Figure 2(a)). However, this
improved vasorelaxation in arteries from rosiglitazone-
treated animals was abolished in the presence of L-NAME
(rosiglitazone-treated: 73 ± 2% versus control 77 ± 2
(Figure 2(b)).
3.5. Endothelium-Independent Relaxation. The shapes of
concentration response curves to SNP were almost identical
in both groups. Moreover, there were no significant differ-
ences in maximum SNP-induced vasorelaxation between the
two groups (rosiglitazone-treated: 88 ± 2%versus control 91
± 2% (Figure 3).
4. Discussion
Rosiglitazone, a thiazolidinedione insulin-sensitizing agent
which acts by stimulating PPAR-γ, has been shown to
improve endothelial function in both human and animals
[20, 24, 25]. Despite reports of expression and function of
PPARγ in rat and human vascular smooth muscle cells [26],
studies in human and rodents have failed to show a direct
vasorelaxant effect of rosiglitazone [27].
The beneficial vascular effects of rosiglitazone involve
vasorelaxation but not vasocontraction mechanism(s). In
fact, it is reported that rosiglitazone had no effect on
contractile responses to NA, but markedly increased sensi-
tivity to Acetylcholine- (Ach-) induced vasorelaxation [28].
Interestingly similar effects of rosiglitazone were seen in this
study, where five-day rosiglitazone treatment did not alter
contractile responses to NA or KCl, while it significantly
improved CCh-induced vasorelaxation indicating a role for
rosiglitazone in improving endothelial function which may
involve upregulation of Akt/eNOS pathways [29].
Although rosiglitazone improved CCh-induced vasore-
laxation, it failed to significantly affect SNP-induced vasore-
laxation suggesting that rosiglitazone does not influ-
ence vasorelaxation via smooth muscle cyclic guanosine
monophosphate (cGMP) pathway. Interestingly a recent
study reported blunting of rosiglitazone effects in lower-
ing blood pressure and vasorelaxation in animals lacking
endothelial but not smooth muscle PPARγ (SM22Cre/flox
mice) [30], indicating that beneficial effects of rosiglitazone
are mediated via activation of specific endothelial PPARγ
receptors. Moreover, in streptozotocin- (STZ-) induced
diabetic rats rosiglitazone significantly reversed blunting of
ACh-induced vasorelaxation [31], further highlighting role
of PPARγ agonists in protecting endothelial function. Similar
effects have also been described on genetically modified
mice where regulation of blood pressure and heart rate
under stressed conditions are consequence of activation
of endothelial PPARγ receptors [32]. Furthermore, stress-
induced (transplantation-induced) endothelial dysfunction
is completely restored by rosiglitazone [33] highlighting
improvement of endothelial function by activation of PPARγ
receptors.
In our study, the increased CCh-induced vasorelaxant
effect of rosiglitazone therapy was abolished in the presence
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Figure 1: The effects of (a) KCl (10–125mM) and (b) noradrenaline (NA; 0.5–6 μM) on arteries from 5-day rosiglitazone-treated and













































Figure 2: Relaxation curves for carbamylcholine (CCh) on arteries from 5-day rosiglitazone-treated and untreated control animals in (a)
absence or (b) presence of L-NAME. Arteries were first precontracted with NA (8 μM). When contraction reached a plateau after 2 minutes,
concentration-response curves to CCh were carried out in the presence or absence of L-NAME (100 μM). Data represent mean± S.E.M. The
concentration-response curves between untreated controls and rosiglitazone-treated animals differ significantly (by ANOVA, ∗P < 0.01) in
the absence of L-NAME but not in the presence of L-NAME.
where presence of L-NAME blocked ACh-induced relax-
ation in pioglitazone-treated STZ-diabetic rats [34]. Taken
together, these data suggest that PPARγ activation improves
endothelial function, thereby facilitating production and/or
release of nitric oxide (NO) vasorelaxant. Although we did
not measure NO levels in this study, others have shown
an increased basal nitric oxide release in TZD-treated STZ-
diabetic rats suggesting inhibition of NO breakdown and/or
increase of basal and agonist-stimulated production of NO
by pioglitazone [35] and rosiglitazone [36], leading to
attenuated endothelial-dependent vasorelaxation.
Rosiglitazone treatment had no effects on total body
weight and gastrocnemius muscle mass. Measurements of
fat pad masses indicated an increase in gonadal but not
in perirenal fat pad mass suggesting selective changes in
adiposity in response to rosiglitazone therapy. The impor-
tance of this selective increase in fat pad remains to be
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Figure 3: Relaxation curves for sodium nitroprusside (SNP)
on arteries from 5-day rosiglitazone-treated and untreated con-
trol animals. NA (8 μM)-precontracted arteries were subjected
to increasing concentration of SNP. There were no significant
differences between the two groups. Data represent mean ± S.E.
on diabetic animal models, rosiglitazone treatment in this
study significantly improved lipid profile of nonobese, lean,
nondiabetic animals by reducing plasma levels of NEFA
and triglyceride, perhaps by diverting circulating lipids
to gonadal fat pad deposition. However, this hypothesis
requires further investigation. Rosiglitazone’s effects on
adipocytes also include increase in adiponectin production
[37] which has been shown to have cardioprotective effects
[37]. Therefore, it is plausible to suggest that increase
in adiponectin together with improved lipid profile may
contribute to beneficial effects of rosiglitazone on vascular
function.
The potential side effects of thiazolidinediones include
oedema and haemodilution at least partially due to an
adipose-tissue-selective activation of PKC and vascular per-
meability [38]. In this study, rosiglitazone treatment signifi-
cantly reduced red blood cell packed volume (haematocrit).
It is possible that lowering haematocrit is a secondary
response to rosiglitazone-induced vasodilatation, which in
turn activates renin-angiotensin system (RAS) [39] with
subsequent haemodilution as a consequence of sodium and
water retention. What is important to note is that despite
significant beneficial effects of TZD’s as an antidiabetic
agents, recent reports have highlighted significant increase
in cardiac related morbidity and mortality, in particular
on development of heart failure in human subjects with
type 2 diabetes mellitus [40–42]. However, there are con-
trasting reports underlining importance of rosiglitazone as
a caridoprotective agent in postmyocardial infarction [37].
These conflicting reports suggest existence of multifactorial
elements of TZD’s effects on cardiovascular function and
hence, their use should be tailored for each individual patient
in question.
In summary, short-term rosiglitazone therapy improves
both metabolic profile and vascular function in lean nondia-
betic rats. The beneficial effect of rosiglitazone on vascular
reactivity is mediated by activation of endothelial PPARγ
receptors leading to increased NO synthesis and production.
This increased NO production may, at least in part, explain
mechanism(s) of blood-pressure-lowering effects of thiazo-
lidinediones on both human and animals models. Moreover,
improved vasorelaxant effect seen by rosiglitazone therapy
in this study appears to be a class effect shared with other
thiazolidinedione compounds.
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